جست‌وجوی استاد و پژوهشگر

Maricel Kannمشاهده پروفایل

دانشیار

• Computational Biology
• Bioinformatics
• Systems Biology
• +۱۲ مورد دیگر

Maricel Kann is an Associate Professor in the Department of Biological Sciences at the University of Maryland, Baltimore County (UMBC), with an affiliate appointment in the Computational Sciences and Engineering Department. Her research integrates computational biology, bioinformatics, and systems biology to understand protein networks, domain-level functional impacts of genetic variants, and molecular mechanisms in diseases such as cancer. Ph.D., University of Michigan, Ann Arbor, 2001 Postdoctorate, National Center for Biotechnology Information, NIH, 2007 Her research focuses on developing computational methodologies to analyze protein domain interactions, prioritize disease-associated variants, and derive molecular signatures of cancers like prostate and breast cancer. She leads projects such as DMDM (Domain Mapping of Disease Mutations) and EMU (Extractor of Mutations), which enable domain-level mutation analysis and text-mining of disease-related variants. Her work emphasizes interdisciplinary collaboration with experimentalists and the integration of genomic, functional, and evolutionary data. Her recent publications reflect a strong trend in domain-centric cancer genomics, statistical modeling of mutation hotspots, and computational frameworks for interpreting non-coding variants and personal genomes. She has contributed significantly to benchmarking in computational biology and the development of tools for translational bioinformatics. NCI Transition Career Development Award (K22) 2009-2012 NIH Intramural Research Training Award 2002-2007 NIH Fellows Award for Research Excellence 2003 Susan Lipschutz Award for Women Graduate Students 1999 Sloan Foundation Summer Graduate Fellowship 1998 Graduate Fellowship of the Organization of the American States 1996-1998 Dr. Kann mentors numerous graduate and undergraduate students through projects like EMU and PINTT (Protein INteraction Text-mining Tool), fostering interdisciplinary training. She has served on editorial boards (e.g., Journal of Biomedical Informatics), advisory committees (PubMedCentral, UniProt), and as organizer for major conferences in bioinformatics. She currently teaches BIOL 495: Seminar in Bioinformatics and is actively recruiting Ph.D. students in computational biology and bioinformatics. Her lab collaborates with researchers across institutions and is part of several interdisciplinary programs including the Chemistry and Biology Interface Program at UMBC and the University of Maryland Greenebaum Cancer Center. She is also involved with the University of Maryland School of Medicine’s Program in Biochemistry and Molecular Biology.

• Cancer Biology
• Neurodegenerative diseases
• Cell cultures
• +۸ مورد دیگر

Alessandro Provenzani is a Full Professor at the Department of Cellular, Computational, and Integrative Biology (CIBIO) at the University of Trento. His research focuses on molecular mechanisms underlying cancer biology, neurodegenerative diseases, and translational control of gene expression. He is particularly interested in RNA-binding proteins such as HuR and their roles in cancer metabolism, drug resistance, and stem cell biology. Provenzani teaches courses including Biology applied to Biotechnology , Cell biology , and Translational Control in Disease , emphasizing stem cell biology, cellular differentiation, and experimental methodologies. His work integrates molecular biology, pharmacology, and systems biology approaches to address translational challenges in cancer and neurodegenerative disorders. Key research themes include: RNA-binding proteins in cancer progression and therapy resistance Metabolic reprogramming in tumors (e.g., NAMPT enzyme roles) Design of small molecules targeting protein-RNA interactions Role of non-canonical translation initiation in disease Recent studies highlight development of HuR inhibitors, modulation of autophagy pathways, and analysis of C9orf72 repeat expansions in ALS/FTD. His lab utilizes advanced techniques like high-throughput screening, CRISPR-based assays, and metabolic profiling.

Yu Chenمشاهده پروفایل

استاد

• Cancer Biology
• Transcription Factors
• Prostate Cancer Oncogenesis
• +۸ مورد دیگر

Yu Chen is a Professor at the Weill Cornell Medicine Graduate School of Medical Sciences, where she leads a research laboratory focused on the molecular mechanisms of prostate cancer. She is affiliated with the Department of Cell & Developmental Biology and contributes to the Tri-Institutional partnership between Weill Cornell, Memorial Sloan Kettering Cancer Center, and Rockefeller University. Her research centers on understanding how key transcription factors—particularly the androgen receptor (AR) and ETS family members—drive oncogenesis in prostate cancer, which typically lacks common oncogenic mutations like RAS or BRAF. Using biochemical and genetic screening approaches, her lab investigates transcriptional regulation, cellular lineage specification, and signal transduction pathways to uncover therapeutic targets. Dr. Chen's work lies at the intersection of cancer biology, molecular biology, and drug discovery. Although no specific publications or articles are listed in the provided text, her research focus suggests strong contributions to understanding transcription factor-driven cancers and identifying novel intervention strategies. Research Focus: Cancer Biology, Transcriptional Regulation, Cell Signaling Affiliation: Cell & Developmental Biology PhD Program Collaborative Environment: Tri-Institutional partnership with Sloan Kettering Institute While no specific scientific awards are mentioned in the provided content, her position as a professor and principal investigator indicates recognition in her field. Similarly, she likely mentors PhD and postdoctoral trainees through the graduate school’s programs, though no named students are listed. The laboratory operates within a robust research ecosystem that supports translational and basic science, with potential involvement in grant-funded projects related to cancer mechanisms and therapeutic development. Dr. Chen’s lab is likely integrated into broader collaborative networks across Weill Cornell and MSKCC, promoting interdisciplinary research in oncology and molecular medicine.

• Prostate cancer
• Stem cell biology
• Glycosylation in cancer
• +۵ مورد دیگر

Laura Wilson is a Research Fellow at Newcastle University's Institute of Genetic Medicine within the Faculty of Medical Sciences, specializing in prostate cancer research. She has maintained a consistent research profile since 2011, primarily collaborating with Professor Rakesh Heer's research group. Her research focuses on the role of glycosylation pathways in prostate cancer progression and metastasis, with particular expertise in sialylation enzymes (ST3Gal1, ST6GAL1), FUT8-mediated fucosylation, and O-glycosylation modifications. She has made significant contributions to understanding how glycan modifications influence tumor immunity through Siglec ligand interactions and how these pathways can be therapeutically targeted. Wilson's recent work (2023-2025) demonstrates a clear progression toward identifying specific glycosylation enzymes as therapeutic targets in prostate cancer. Her publications reveal a sophisticated understanding of how post-translational modifications of cell surface proteins affect tumor growth, metastasis to bone, and immune evasion mechanisms. The consistent appearance of her work in high-impact prostate cancer research indicates her contributions are recognized as significant within the field. She has also contributed to prostate stem cell biology, developing human prostate organoid models and investigating the role of stem cells in prostate development and cancer initiation. Her early work (2011-2013) established her expertise in prostate stem cell characterization and lineage tracking.

• Prostate Cancer
• Bladder Cancer
• Cancer Stem Cells
• +۵ مورد دیگر

Professor Rakesh Heer is affiliated with Newcastle University and actively contributes to prostate and bladder cancer research. His work focuses on molecular mechanisms, stem cell dynamics, and translational approaches. Academic Rank: Professor Research Themes: Prostate Cancer, Bladder Cancer, Cancer Stem Cells, Induced Pluripotent Stem Cells (iPSCs), Androgen Receptor Signaling, Glycosylation Pathways Recent publications highlight his exploration of glycobiology in prostate cancer immunity (e.g., ST3Gal1 and ST6GAL1 roles) and AI applications in bladder cancer recurrence prediction. He also investigates OXPHOS defects , prostate organoids , and clinical trial methodologies for castration-resistant prostate cancer. Professor Heer collaborates extensively on iPSC-based cancer models and urological surgical techniques , including photodynamic diagnosis and focal therapy. His work bridges fundamental molecular biology, translational research, and clinical practice.

• Prostate Cancer
• Glycobiology
• Molecular Biology
• +۳ مورد دیگر

Dr. Jennifer Munkley is a researcher affiliated with Newcastle University, focusing on prostate cancer biology and glycobiology. Her work explores glycosylation, sialylation, and androgen-regulated processes in cancer progression. Research Interests Her research spans: Glycobiology in cancer metastasis Androgen receptor signaling RNA splicing in oncogenesis Glycan-based therapeutic strategies Publications Key trends in her publications include: Targeting glycosylation enzymes (e.g., ST3Gal1, ST6GAL1) to inhibit tumor growth. Role of aberrant sialylation in drug resistance and immune evasion. Linking glycan modifications to prostate cancer bone metastasis. Investigating androgen-regulated genes and splicing patterns. Metabolic inhibitors as tools for glycan-based cancer therapy. Functional roles of glycosylation in tumor microenvironment dynamics.

• Mitochondrial Genetics
• Androgen Receptor Signaling
• Prostate Cancer
• +۳ مورد دیگر

Dr. Richard Temperley is a researcher at Newcastle University specializing in mitochondrial genetics and androgen receptor signaling. His work primarily focuses on gene expression regulation, transcription dynamics, and RNA stability in human mitochondria, with applications in prostate cancer research and molecular biology. He has collaborated extensively with scientists such as Professor Robert Lightowlers and Professor Zofia Chrzanowska-Lightowlers. Mitochondrial RNA stability and decay pathways Androgen receptor-mediated transcription mechanisms Prostate cancer molecular biology Translation regulation and ribosome function

• Prostate Cancer
• Molecular Oncology
• Targeted Therapy
• +۳ مورد دیگر

Dr. Emma Lishman-Walker is a researcher at Newcastle University specializing in molecular oncology with a primary focus on prostate cancer therapeutics and epigenetic mechanisms. Her work centers on identifying novel molecular targets for advanced prostate cancer treatment. Her research interests encompass: Prostate Cancer Pathobiology Epigenetic Modifications in Cancer Progression Kinase Signaling Pathways Therapeutic Target Validation Castration-Resistance Mechanisms Molecular Drivers of Therapy Resistance Recent publications demonstrate her expertise in prostate cancer molecular pathways, with 2024 research exploring Casein Kinase 1α as a therapeutic target and 2023 work investigating KMT5A-mediated epigenetic regulation of CDC20. These studies collectively advance understanding of molecular vulnerabilities in treatment-resistant prostate cancer through integrated approaches to kinase signaling and epigenetic control.

Leon Brokkenمشاهده پروفایل

مدرس

• Endocrinology
• Molecular Genetics
• Reproductive Toxicology
• +۳ مورد دیگر

Leon Brokken serves as a University Lecturer in Biomedical Laboratory Science within the Faculty of Natural Sciences at Malmö University, specifically in the Department of Bioanalysis. His academic foundation includes a PhD from the University of Amsterdam focused on pituitary TSH-receptor mechanisms. His research spans critical areas in endocrinology and molecular genetics, with particular emphasis on hormone receptor signaling pathways, polymorphisms affecting reproductive health, and cancer biology. Key investigations explore aryl hydrocarbon receptor interactions in male reproductive toxicity and prostate cancer mechanisms. Recent publications reveal a strong trend toward translational biomedical research, with 2023 work advancing alternatives to fetal calf serum in cancer cell cultures. Earlier seminal studies (2013-2014) established connections between genetic polymorphisms, environmental pollutants, and reproductive pathologies including testicular cancer and semen quality deterioration. With an h-index of 17 and 1,148 citations, his fingerprint highlights Pituitary (100%), TSH Receptor (74%), Polymorphism (65%), and Prostate Cancer (60%) research domains. Current work demonstrates continued focus on reducing animal products in laboratory research while maintaining rigorous cancer modeling standards. His supervision portfolio includes one documented supervised work, primarily focused on molecular mechanisms in reproductive toxicology. Research outputs show consistent productivity since 1995 with notable publication clusters in 2006, 2013, and 2014, reflecting sustained engagement in endocrine disruption and cancer biology.

Jason Heindlمشاهده پروفایل

دانشیار

• Microbiology
• Bacterial cell biology
• Biofilms
• +۲ مورد دیگر

Jason Heindl, Ph.D., is an Associate Professor in the Department of Biological & Biomedical Sciences at Rowan University's College of Science & Mathematics. His research focuses on bacterial cell biology, biofilms, and prokaryotic development, with emphasis on Agrobacterium tumefaciens as a model system. He teaches courses in Microbiology and integrates research with pedagogy through initiatives like the CURE program. Education: • B.A. in Biology from Amherst College (1997) • Ph.D. in Microbiology from Harvard University (2010) • Postdoctoral Fellow at Indiana University (2010–2015) Research Expertise: Dr. Heindl investigates molecular mechanisms of bacterial attachment, motility, and biofilm formation. His work spans antimicrobial development, signal transduction pathways, and genetic regulation in pathogenic bacteria. Key themes include cyclic-di-GMP signaling, metal ion homeostasis, and polyamine metabolism in microbial systems. Publication Trends: His 15 most recent articles (2014–2025) cluster in microbiology, antimicrobial chemistry, and bacterial genetics. Dominant topics include biofilm disruption strategies, Agrobacterium virulence regulation, and structure-activity relationships in drug design. Educational research on STEM identity transformation via microbial models is an emerging focus.

• Medical Oncology
• Internal Medicine
• Cancer Biomarkers
• +۴ مورد دیگر

Professor Cemil Bilir is a distinguished Medical Oncology specialist at Recep Tayyip Erdoğan University's Faculty of Medicine, Department of Internal Medicine. With extensive clinical and research experience, he contributes significantly to cancer research and patient care in Turkey. His educational background includes: Graduated from Istanbul University Faculty of Medicine (2004) Completed Internal Medicine specialization (2005-2010) Finished Medical Oncology subspecialty training (2010-2013) Professor Bilir's research focuses on molecular mechanisms in cancer progression, particularly examining TGF-β, IL-6/JAK/STAT3, and TLR4 signaling pathways in breast, lung, and prostate cancers. His work bridges basic science discoveries with clinical applications, investigating how natural compounds like curcumin and established therapies like zoledronic acid affect cancer progression and patient outcomes. Recent studies have explored cancer cachexia mechanisms, treatment response biomarkers, and the relationship between renal function and chemotherapy efficacy. His publication record shows consistent productivity with research spanning from 2006 to 2020, demonstrating evolving expertise from general internal medicine topics to specialized oncology research. The most recent publications (2018-2020) reveal a strong focus on molecular oncology and targeted therapies. Professor Bilir's scientific recognition includes: 3rd Prize in Best Research (2016) As an active researcher and clinician, Professor Bilir contributes to the Turkish Oncology Group and participates in multi-institutional cancer research across Turkey. His work provides valuable insights into cancer treatment optimization and biomarker discovery for Turkish patient populations.

Rytis Prekerisمشاهده پروفایل

استاد

• Cell Polarization
• Protein Targeting
• Cancer Metastasis
• +۳ مورد دیگر

Rytis Prekeris, Ph.D., is a Professor and Director of the Molecular Biology Graduate Program at the University of Colorado Anschutz Medical Campus. His research focuses on cell polarization, protein targeting, and their roles in development and cancer. He collaborates with experts in microRNA (Dr. Paul Jedlicka) and breast cancer (Dr. Tracy Lyons) to study mechanisms of metastasis. Research Interests: Epithelial cell polarization, Rab GTPases, midbody signaling, cancer metastasis, and stem cell proliferation. Methodologies: Combines in vitro (MDCK cultures) and in vivo (zebrafish) models with cell/molecular biology techniques. Key Projects: Molecular mechanisms of apical lumen formation in epithelial tissues Targeted MMP secretion via invadopodia in breast cancer Midbody inheritance regulation in post-mitotic cells Recent Publications: Explore Rab GTPase regulation of cell division, midbody signaling in stemness, and Cx43 inhibitor phosphorylation dynamics.

Derek Allisonمشاهده پروفایل

دانشیار

• Cytopathology
• Molecular surgical pathology
• Cancer metabolism
• +۷ مورد دیگر

Derek Allison, MD, is Associate Professor of Pathology and Laboratory Medicine at the University of Kentucky College of Medicine, Vice-Chair for Research, Assistant Director of the Biospecimen Procurement & Translational Pathology Shared Resource, and Director of the Molecular Tumor Board at the Markey Cancer Center. His federally funded translational program bridges high-volume cytopathology service with multi-omic cancer metabolism, glycomics, and AI-driven predictive biomarkers. Education & Training: BS Biochemistry, Lipscomb University (2010) MD, Georgetown University (2014) AP/CP Residency, Johns Hopkins University School of Medicine (2018) Cytopathology Fellowship, Johns Hopkins University School of Medicine (2019) Research Focus: Dr. Allison’s group uses spatial mass-spectrometry imaging, single-cell sequencing, and machine learning to decode metabolic heterogeneity in lung and prostate cancers. Major themes include glycogen and N-glycan drivers of tumor initiation, PLK1-mediated therapy resistance, and AI-powered pathology assays that predict response to intravesical BCG in high-risk bladder cancer. Recent Publication Trends: From 2021-2025 he has >60 peer-reviewed articles centered on three intersecting tracks: (1) glycomics/glycogen biology in lung adenocarcinoma and pulmonary fibrosis, (2) PLK1 and kinase signaling in prostate and lung cancers, and (3) real-world validation of AI biomarkers in urothelial malignancies. His work consistently appears in high-impact journals such as Nature Metabolism , Nature Communications , Cell Reports Medicine , and Cancer Cytopathology . Leadership & Service: He directs the Molecular Tumor Board at Markey Cancer Center, leads the BPTP biobank, and serves on multiple NCI-funded consortia for precision oncology. He mentors pathology residents, graduate students, and clinical fellows in projects spanning interventional cytopathology to computational metabolomics.

Jeremy Meierمشاهده پروفایل

استادیار

• T-Cell Signal Transduction
• Tumor Microenvironment
• Mitochondrial Function in Immune Cells
• +۵ مورد دیگر

Jeremy Meier is an Assistant Professor at the University of North Carolina at Chapel Hill School of Medicine, affiliated with the Immunology Department and the Bone Marrow Transplant and Cellular Therapy Program. His research focuses on T-cell signal transduction pathways, mitochondrial function in immune cells, and therapeutic targets for cellular therapeutics in cancer. Hematology Immunology Dr. Meier's work explores how extracellular signals regulate mitochondrial function in T-cells, impacting tumor immunity and long-term effectiveness of cellular therapies. He has published extensively on immunometabolism, cancer immunotherapy, and signal transduction mechanisms. His recent publications highlight trends in tumor microenvironment studies, STAT3 signaling, and lipid metabolism in T-cells. Articles span journals like Cell Metabolism , Science Signaling , and Nature , reflecting interdisciplinary research at the intersection of immunology, oncology, and molecular biology. Scientific recognition includes: 2024 Scholar Award, American Society of Hematology 2024 UNC Physician Scientist Faculty Award 2023 Pope Clinical Trainee Award 2023 Young Investigator Award, American Society of Clinical Oncology 2022 Outstanding Fellow Award, North Carolina Oncology Association 2014 Ruth L. Kirschstein National Research Service Award Dr. Meier's contributions to understanding T-cell dynamics in transplantation and cancer therapy are pivotal, with ongoing work targeting mitochondrial pathways for improved immunotherapies.

Kevin Huynhمشاهده پروفایل

پژوهشگر ارشد

• Lipidomics
• Mass spectrometry
• Lipid Metabolism
• +۴ مورد دیگر

Dr. Kevin Huynh is a Research Fellow and Group Leader at the Baker Heart and Diabetes Institute, holding an NHMRC Emerging Leadership Fellowship. He maintains academic appointments at both La Trobe University within the Baker Department of Cardiovascular Research, Translation and Implementation and at the University of Melbourne within the Baker Department of Cardiometabolic Health. Dr. Huynh's educational background includes: Bachelor of Science in Human Pathology from the University of Melbourne Honours year completed in 2011 at the University of Melbourne examining secretases in Alzheimer's disease PhD completed in 2019 from Monash University under Professor Peter Meikle and Associate Professor Brian Drew Dr. Huynh's research focuses on developing mass spectrometry techniques for lipid analysis, with particular emphasis on understanding lipid metabolism in neurodegenerative and metabolic diseases. His laboratory has established a comprehensive lipidomics platform that enables high-throughput profiling of lipid metabolites in human plasma. This platform has been instrumental in characterizing lipid signatures associated with Alzheimer's disease, type 2 diabetes, and cardiovascular conditions. His recent publications demonstrate a strong trend toward understanding the relationship between lipid metabolism and disease mechanisms through large cohort studies and multi-omics integration. His work increasingly incorporates machine learning approaches to analyze complex lipidomic datasets and identify biomarkers for early disease detection and risk stratification. Dr. Huynh's scientific achievements include: NHMRC EL1 Investigator grant (2021–2025) for research on lipid metabolism in Alzheimer's disease ARC Discovery Project grant as Chief Investigator A (2023–2025) for novel lipidomic analysis methods Sir Laurence Muir Prize from Baker Institute (2021) John Funder Award for Best Early Career Scientist presentation (2021) Multiple invitations to present at international conferences including the Metabolomics Society and ASMS As a Group Leader, Dr. Huynh oversees a research program that has secured significant funding and established collaborations across multiple institutions. His NHMRC fellowship supports his investigation into lipid metabolism in Alzheimer's disease using peripheral immune cells, while his ARC Discovery Project focuses on developing high-throughput lipidomic analysis approaches. Dr. Huynh leads the Metabolomics Laboratory at the Baker Heart and Diabetes Institute, where his team specializes in mass spectrometry-based lipid analysis. The laboratory has developed advanced methodologies for high-throughput lipid profiling and has contributed significantly to understanding the lipid signatures associated with various diseases, with strong connections to clinical researchers for translational applications.